Groupe d'Etude en Oncologie du Quebec

Title	A Phase 3, Two-Stage, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
Protocole ID	EXCALIBER-RRMM (CC-220-MM-002)
ClinicalTrials.gov ID	NCT04975997
Cancer Type(s)	Myeloma
Phase	Phase III
Stage	Relapse/refractory (2nd line and more)
Study Type	Clinical
Drug	Iberdomide, daratumumab et dexaméthasone (IberDd) versus daratumumab, bortézomib et dexaméthasone (DVd)
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL HOPITAL DE L'ENFANT-JESUS 1401 18e Rue, Québec, QC, G1J 1Z4
City
Principal Investigator	Dr. Marc Lalancette
Coordinator	Patricia Chabot 418-525-4444 poste 15769
Status	Recruiting
Activation Date	01-12-2022
Eligibility Criteria	Documented diagnosis of multiple myeloma (MM) and measurable disease Received 1 to 2 prior lines of anti-myeloma therapy Must have documented disease progression during or after their last anti-myeloma regimen Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or 2
Exclusion Criteria	Any condition that confounds the ability to interpret data from the study Has plasma cell leukemia, Waldenstrom's macroglobulinemia or POEMS syndrome (polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes), or clinically significant amyloidosis Known central nervous system involvement with MM Prior therapy with iberdomide Other protocol-defined inclusion/exclusion criteria apply

Groupe d'étude en oncologie du Québec